HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trans fatty acids

This article was originally published in The Tan Sheet

Executive Summary

FDA reopens until Jan. 19 comment period on prudence of listing trans fatty acids in "Nutrition Facts" labeling and whether terms "reduced trans fat" and "reduced saturated and trans fat" should be better defined in nutrient content claims for foods, including dietary supplements, according to recent Federal Register notice. Proposed rule was published by agency Nov. 17, 1999 (1"The Tan Sheet" Nov. 15, 1999, In Brief)

You may also be interested in...



Trans Fat Footnote Statement On Food, Supplement Labeling Proposed By FDA

FDA is seeking comments on the proposed use of a footnote statement on food and dietary supplement products containing trans fat that would advise consumers against excessive intake of the ingredient

Trans fatty acids

Food marketers would be required to disclose the trans fatty acids content of products in the "Nutrition Facts" panel under an FDA proposed rule expected to be published in the Nov. 17 Federal Register. The levels of trans fat also would be considered when attempting to meet the requirements for claims regarding "low saturated fat" and "reduced saturated fat," as well as "lean," "extra lean" and cholesterol claims. Products containing more than 4 g saturated and trans fat combined per serving additionally would be prohibited from making health claims, such as the approved claim for calcium and osteoporosis. The public comment period on the proposal will run for 90 days

People In Brief

Perrigo promotes in pricing, planning

Topics

UsernamePublicRestriction

Register

RS132860

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel